In a recent development on the United States’ health regulatory front, the Food and Drug Administration (FDA) has taken action against Abiomed for disregarding certain approval protocols pertaining to its Impella Connect System software. According to details made available, the company failed to seek the necessary approval before introducing the software to the market. Click here for the details.
This software is specifically designed to work in unison with the company’s Automated Impella Controller (AIC). For context, the AIC forms a significant part of a far-reaching medical device system that provides temporary ventricular support. Its primary role is to assist a patient’s heart in pumping blood during crucial clinical situations.
The FDA’s decision to issue a warning letter to Abiomed signifies an important moment for the broader digital health technology sector. It serves as a reminder of the strict regulations in place that ensure patient safety and calls for diligent adherence to such protocols before the market launch of any medical-related software.